Compugen Ltd. has announced significant leadership changes effective September 2025, with current CEO Anat Cohen-Dayag transitioning to Executive Chair and CSO Eran Ophir being appointed as the new President and CEO.
Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.
The FDA approved FoundationOne Liquid CDx as a companion diagnostic for niraparib and abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.